Seeking Alpha

Baird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance...

Baird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance especially after this weekend's ASCO meeting in which both Bristol Myers (BMY flat) and Medivation (MDVN -2%) published impressive trial results for their prostate drugs. The firm loweres its 2014 and 2015 estimates for Provenge and said the drug may have trouble remaining relevant.
From other sites
Comments (1)
  • shakazoid
    , contributor
    Comments (243) | Send Message
     
    Dr Cohen , where are you. Wanna see your usual +ve response and hope you have not sold out yet. :)
    4 Jun 2012, 04:37 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs